The Evolving Role of ADCs in NSCLC: A Focus on TROP2-Directed Therapies

Anne S. Tsao, MD, and Edward B. Garon, MD, MS, introduce themselves and provide an overview of the incidence, prognosis, and treatment of non–small cell lung cancer.

Thoracic medical oncologists discuss the evolving role of biomarkers in the non–small cell lung cancer treatment landscape.

Expert perspectives on unmet needs in the NSCLC treatment landscape and the role of antibody-drug conjugates in addressing them.

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, provide an overview of TROP2 as a target for patients with non–small cell lung cancer.

A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.

Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.

Comprehensive insights on clinical trial data that have led to further development of sacituzumab govitecan for patients with non–small cell lung cancer.

Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.

A brief overview of clinical trials investigating datopotamab deruxtecan in patients with non–small cell lung cancer.

Edward B. Garon, MD, MS, reviews the safety profiles of sacituzumab govitecan and datopotamab deruxtecan in patients with non–small cell lung cancer.

An overview of clinical trials investigating datopotamab derutecan in patients with non–small cell lung cancer.

Expert perspectives on clinical trials investigating doublet and triplet therapy with datopotamab deruxtecan in patients with non–small cell lung cancer.

Medical oncologists discuss where antibody-drug conjugates fit in the overall non–small cell lung cancer treatment landscape and review the ongoing EVOKE-01 and EVOKE-03 clinical trials.

Thoracic oncologists discuss the progress made and unmet needs that remain in the non–small cell lung cancer treatment space.

Anne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.